-
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
•
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based procurement (VBP) tenders for several pharmaceutical products. A joint statement issued by the National Drug Alliance Procurement Office and the Shanghai Pharmaceutical Centralized Bidding Procurement Management Office cited public complaints regarding the bidding and pricing…
-
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
•
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD 55.2 million) in a Series D+ financing round. The round was co-led by GTJA Investment and KingRay Capital, a state-owned investor focused on small and micro enterprises. Additional participants in the financing round included Guojin…
-
Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care
•
Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a strategic partnership with AGE Dr. Hospital Management Group (Boao Yiling), a leading hospital management group. The collaboration will focus on key areas such as department construction, talent development, technical collaboration, and joint scientific research initiatives.…
-
Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment
•
Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in China, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its HER2 antibody reagent, which is utilized for immunohistochemistry. This new product is designed for the in vitro…
-
Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative antibody-drug conjugate (ADC), BL-B01D1. The approval allows for the combination of BL-B01D1 with a PD-1 inhibitor, with…
-
Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
•
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval from Macau for its cancer therapy Pemazyre (pemigatinib). The drug is indicated for patients with advanced, metastatic, or unresectable cholangiocarcinoma, who have been previously treated with at least one systemic therapy and have confirmed FGFR2…
-
Kintor Pharmaceutical’s GT20029 Meets Primary Endpoint in Phase II AGA Trial
•
Kintor Pharmaceutical Ltd (HKG: 9939), a clinical-stage biotechnology company, has announced that its Phase II clinical study for GT20029, a first-in-class proteolysis targeting chimera (PROTAC) compound, has met its primary endpoint in the treatment of male androgenetic alopecia (AGA) in China. The multi-center, randomized, double-blind, placebo-controlled study aimed to evaluate…
-
Jiangsu Hengrui Medicine Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released its financial report for 2023, recording RMB 22.82 billion (USD 3.15 billion) in revenues for the year, marking a 7.26% increase year-on-year (YOY). The net profit attributable to shareholders, after adjustments for non-recurring gains and…
